Skip to content
ClinCalc Pro
Menu
Opioid Analgesic (Ultra-Potent) Pregnancy: Data in pregnant women insufficient to inform drug-associated risk; extended use in pregnancy may cause neonatal opioid withdrawal syndrome. Embryolethality/maternal toxicity in animals.

Sufentanil

Brand names: Sufenta, Dsuvia (sublingual)

Sufentanil is a potent synthetic opioid used for analgesia during anaesthesia and, in some settings, for neuraxial and acute pain management.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: Analgesic adjunct to general anaesthesia: initiate at 1 to 2 mcg/kg IV (slow injection or infusion).
Route: Intravenous (slow injection or infusion); also epidural
Frequency:
Max: As adjunct to general anaesthesia: up to 8 mcg/kg; maintenance total dosage 1 mcg/kg/hr or less of expected surgical time. As primary anaesthetic agent: doses >=8 mcg/kg.
US labelling (Hospira). Individualise dose by age, weight, physical status, other drugs, type of anaesthesia and procedure. Dosage by anaesthesia duration - 1 to 2 hours: 1-2 mcg/kg (~75% or more may be given before intubation); 2 to 8 hours: 2-8 mcg/kg. Incremental supplements 10-25 mcg (1-2 h cases) or 10-50 mcg (2-8 h cases) as needed for surgical stress. Epidural for labour and delivery: 10-15 mcg with 10 mL bupivacaine 0.125% (with or without epinephrine). Elderly: start at low end of range and titrate slowly. Paediatric: IV use documented in a limited number of patients as young as 1 day undergoing cardiovascular surgery; neonatal clearance ~half that of adults and further reduced in cardiovascular disease - no clean per-kg paediatric dose stated; verify against a children's formulary. Schedule II controlled substance.

Dose auto-extracted from US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to sufentanil (e.g. anaphylaxis)

Side effects

  • Apnoea
  • Skeletal muscle rigidity
  • Bradycardia
  • Respiratory depression
  • Hypotension

Interactions

  • CYP3A4 inhibitors (e.g. macrolide antibiotics, azole antifungals, protease inhibitors): increased/prolonged opioid effects - consider dose reduction
  • Benzodiazepines and other CNS depressants: profound sedation, respiratory depression, coma, death
  • Serotonergic drugs: risk of serotonin syndrome

Clinical monograph

How it works

It is a highly potent selective mu-opioid receptor agonist, producing profound analgesia and dose-dependent central nervous system depression.

Prescribing in practice

  • Owing to its high potency it causes profound dose-dependent respiratory depression and must be used only where airway management and ventilatory support are immediately available.
  • Effects, including respiratory depression, are potentiated by other central nervous system depressants and can outlast a single opioid antagonist dose, requiring continued observation.
  • It can cause bradycardia, hypotension and muscle rigidity, particularly with rapid administration.

Monitoring

Continuous monitoring of respiration, oxygenation and haemodynamics is required during and after administration.

Counselling the patient

  • This is a very potent opioid given by trained anaesthetic staff with close monitoring.
  • Drowsiness and slowed breathing can occur and are watched for closely.

Evidence & guidelines

Its high potency and use as an opioid analgesic in anaesthesia are well established and described in the SPC.

Reference: OAA Guidelines on Labour Analgesia; Miller's Anaesthesia 9th Ed; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.